Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 11, 2015, Pages 1162-1174

  Attwood, S E ^a   Ell, C ^b   Galmiche, J P ^c   Fiocca, R ^d   Hatlebakk, J G ^e   Hasselgren, B ^f   Langstrom, G ^f   Jahreskog, M ^f   Eklund, S ^f   Lind, T ^f   Lundell, L ^g  

^a NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c HÔTEL DIEU   (France)

^d UNIVERSITY OF GENOA   (Italy)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f ASTRAZENECA R AND D   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CYANOCOBALAMIN; ESOMEPRAZOLE; FERRITIN; FOLIC ACID; GASTRIN; HEMOGLOBIN; IRON; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ANEMIA; ANGINA PECTORIS; APPENDICITIS; ARTICLE; BRAIN INFARCTION; CAUSE OF DEATH; CHOLELITHIASIS; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FAINTNESS; FEMALE; FOLIC ACID BLOOD LEVEL; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCISIONAL HERNIA; INGUINAL HERNIA; INJURY; INTERVERTEBRAL DISK HERNIA; INTESTINE INFECTION; IRON BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OSTEOARTHRITIS; PAIN; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATITIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALMONELLOSIS; STOMACH ULCER; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; ADVERSE EFFECTS; AGED; COMPARATIVE STUDY; LAPAROSCOPY; METABOLISM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

AGED; CHROMOGRANIN A; ESOMEPRAZOLE; FEMALE; GASTRINS; GASTROESOPHAGEAL REFLUX; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84929134452     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13194     Document Type: Article

References (33)

1. Moayyedi P, Leontiadis GI,. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 2012; 9: 132-9.
2. Reimer C,. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27: 443-54.
3. Ali T, Roberts DN, Tierney WM,. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122: 896-903.
4. Agewall S, Cattaneo M, Collet JP, et al,. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34: 1708-13.
5. Chen J, Yuan YC, Leontiadis GI, Howden CW,. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46: 93-114.
6. Fiocca R, Mastracci L, Attwood SE, et al,. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012; 36: 959-71.
7. Fiocca R, Mastracci L, Engstrom C, et al,. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am J Gastroenterol 2010; 105: 1015-23.
8. Lundell L, Miettinen P, Myrvold HE, et al,. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009; 7: 1292-8.
9. Lundell L, Attwood S, Ell C, et al,. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008; 57: 1207-13.
10. Galmiche JP, Hatlebakk J, Attwood S, et al,. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969-77.
11. Freston JW, Hisada M, Peura DA, et al,. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2009; 29: 1249-60.
12. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB,. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399-406.
13. FDA. FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109037.htm and http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143258.htm2007 (accessed 16 September 2014).
14. Bhatt DL, Cryer BL, Contant CF, et al,. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
15. O'Donoghue ML, Braunwald E, Antman EM, et al,. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
16. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E,. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 1991; 100: 311-9.
17. Jianu CS, Fossmark R, Viset T, et al,. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644-9.
18. Ito T, Jensen RT,. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010; 12: 448-57.
19. Marcuard SP, Albernaz L, Khazanie PG,. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994; 120: 211-5.
20. Valuck RJ, Ruscin JM,. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 422-8.
21. Yang YX, Lewis JD, Epstein S, Metz DC,. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
22. 2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76-83.
23. Targownik LE, Lix LM, Leung S, Leslie WD,. Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904.
24. Kaye JA, Jick H,. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-9.
25. Garcia Rodriguez L, Cea Soriano L, Ruigomez A, Johansson S,. A UK primary care study on acid-suppressive drugs and hip fracture: is there a link? Gut 2011; 60 (Suppl. 3): A36.
26. Garcia Rodriguez LA, Ruigõmez A, Panes J,. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5: 1418-23.
27. Neal KR, Scott HM, Slack RC, Logan RF,. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996; 312: 414-5.
28. Cunningham R, Dale B, Undy B, Gaunt N,. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243-5.
29. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB,. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-60.
30. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J,. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-5.
31. Sarkar M, Hennessy S, Yang YX,. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-8.
32. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA,. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 792-802.
33. Estborn L, Joelson S,. Frequency and time to onset of respiratory tract infections in esomeprazole and placebo treated patients in 24 randomized controlled trials (UEGW 2013 poster P1617) 2013.